The global non corticosteroid anti-inflammatory eyedrops market experienced significant growth in 2020 and is projected to continue growing at a substantial CAGR in the forecast period. The increasing incidence of cystoid macular edema (CME) globally and the growing need for improving visual acuity after cataract surgery in patients without any risk factors are the major drivers of market revenue growth.

Non corticosteroid anti-inflammatory drugs are highly effective in reducing CME detected by optical coherence tomography or angiography and in improving the speed of visual recovery after eye surgery. These drugs have become a crucial adjunctive tool for various surgeons performing routine as well as complicated cataract surgery, reducing pain, preventing intraoperative miosis, modulating postoperative inflammation, and reducing the incidence of CME. Manufacturers in the market are partnering with various pharmaceutical industry players to launch their composition of non corticosteroid anti-inflammatory eyedrops, augmenting market size and overall revenue growth.

However, limited awareness regarding the effectiveness of non corticosteroid anti-inflammatory drugs and their high cost are the factors expected to restrain the overall revenue growth of the market. The non corticosteroid anti-inflammatory eyedrops market is segmented into Ocufen, Mugabe, Diclofenac, and others based on types. The Ocufen segment accounted for the largest market share in the global market in 2020, owing to growing preference of this type of drug by surgeons to reduce post-surgery eye inflammation. In terms of applications, the adult segment is expected to register the highest revenue CAGR during the forecast period, due to increasing rate of CMEs developed by adults and rising adoption of non-corticosteroid anti-inflammatory eye drops among adults due to its enhanced effectiveness.

Request a sample Report of non corticosteroid anti-inflammatory eyedrops market https://www.reportsanddata.com/download-free-sample/400

North America is expected to account for a comparatively larger revenue share than other regional markets during the forecast period, owing to growing expenditure in healthcare, increasing incidence of eye inflammation, and high investments in R&D to develop effective non-corticosteroid anti-inflammatory drugs to reduce pain and occurrence of inflammation after surgery. The Asia Pacific market revenue share is expected to increase significantly between 2021 and 2028, due to growing demand for drugs to reduce pain caused by CME and rapid growth in the healthcare industry in the region.

Leading players in the non corticosteroid anti-inflammatory eyedrops market include Novartis AG, Alcon, Bausch & Lomb Inc, Allergan, Inc., Visine, Meda Pharmaceuticals Inc, Bausch & Lomb, Similasan Corporation, Cigna, Viva Opti-Free, Clear eyes, Systane, Staples, Rite Aid, and Walgreens. Major companies are adopting various strategies, including mergers, acquisitions, partnerships, and new product development, among others to stay ahead of the competition and expand market footprint and revenue share. The report offers industry analysis and competitive landscape, company financials, and impact analysis. It includes a detailed view of the global non corticosteroid anti-inflammatory eyedrops market, along with changing dynamics and trends, scenarios, detailed market and regional segmentation, regional landscape, analysis and evaluation, major investments, product offerings, product launches, and details of historical, current, and projected revenues.

Non corticosteroid anti-inflammatory eyedrops market segmentation:

Type Outlook (Revenue, USD Billion, 2018 - 2028)

• Ocufen
• Mugabe
• Diclofenac
• Others

Application Outlook (Revenue, USD Billion, 2018 – 2028)

• Adult
• Children

Regional Outlook (Revenue, USD Billion, 2018 - 2028)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• BENELUX
• Rest of Europe
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of APAC
• MEA
• Saudi Arabia
• UAE
• South Africa
• Rest of MEA

Request a customized copy of the report https://www.reportsanddata.com/request-customization-form/400

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs